Lanpo

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanpo

Property Description
Active ingredient Lansoprazole
Form Delayed-release capsules, orodispersible tablets
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid secretion
Origin Synthetic, substituted benzimidazole prodrug

Lanpo is a medication primarily identified by its active pharmaceutical ingredient, Lansoprazole, and belongs to the therapeutic class of Proton Pump Inhibitors (PPIs). This compound is a synthetic substituted benzimidazole prodrug, functioning as a powerful gastric antisecretory drug. Its core mechanism, clinically recognized for its consistency in blocking acid production, is to achieve profound and long-lasting inhibition of gastric acid secretion, which is the fundamental action of its entire class.

The medication is formulated as a single active ingredient product, commonly available in oral dosage forms such as delayed-release capsules and orodispersible tablets. This specific preparation is required because Lansoprazole is an acid-labile compound that must be protected from stomach acid for effective absorption. The formulation utilizes specialized enteric-coated pellets contained within the capsule, ensuring the prodrug survives the acidic environment to be absorbed in the small intestine. The differentiation of some versions, such as the orodispersible tablet, facilitates simpler administration for specific patient groups.

General Purpose: Reducing Gastric Acid Secretion

The general purpose of this medication is the persistent and powerful control over the acidity levels within the stomach and the upper gastrointestinal tract. The efficacy of this mechanism involves the sustained blockade of the final step of acid production in the parietal cells, which provides a key clinical benefit. This means the medication provides a mechanism for lasting relief by consistently lowering the corrosive potential of gastric contents. This foundational action is utilized, for instance, in typical neutral use scenarios where sustained acid reduction is required for the healing process.

What side effects are possible with Lanpo?

Possible Side Effects and Safety Information

Lanpo (Lansoprazole) has an officially documented safety profile, with potential adverse reactions systematically classified by government regulatory authorities based on clinical data and post-marketing surveillance.

Adverse Reaction Classification

The most frequently reported adverse reactions are classified as Common, affecting the Gastrointestinal System (including diarrhea, abdominal pain, nausea, vomiting, flatulence, and constipation) and the Nervous System (headache and dizziness). Reactions classified as Uncommon include fatigue, joint pain (arthralgia), muscle pain (myalgia), and increases in liver enzyme values.

Serious and Long-Term Safety Concerns

The official labeling documents rare but serious adverse reactions, including immune-mediated conditions such as Acute Tubulointerstitial Nephritis (TIN) and severe skin reactions known as SCARs (Severe Cutaneous Adverse Reactions).

Specific risks are explicitly tied to the duration of exposure. Long-term use (typically over one year) is associated with an increased risk of Hypomagnesemia (low magnesium levels in the blood) and Bone Fracture (hip, wrist, or spine). Extended daily use (e.g., beyond three years) is also linked to a potential risk of Vitamin B12 deficiency.

Safety Restrictions and Context

Regulatory safety notes advise caution for individuals with Hepatic Impairment. The official profile also includes a critical restriction that the symptomatic response experienced by a patient should not be assumed to exclude the presence of a gastric malignancy. Furthermore, official sources note a potential for the medication to increase the risk of gastrointestinal infections (e.g., Salmonella and Campylobacter) due to reduced stomach acidity.

Overdose and Emergency Response

The official regulatory profile for Lansoprazole overdose indicates that clinical experience with large acute ingestions is limited. No specific severe or life-threatening manifestations are uniquely documented as a direct result of acute overdose. Clinical trial data involving high oral doses (up to 1,800 mg) reported general adverse reactions, most commonly including diarrhea, abdominal pain, nausea, and constipation. This limited data suggests a primary focus on the immediate regulatory response.

Required Emergency Action

When an overdose is suspected, regulatory authorities mandate that emergency medical attention be sought immediately. This instruction includes contacting a Poison Control Center or a regional emergency department, even if the individual is not exhibiting severe symptoms.

Supportive Management

The management strategy for Lansoprazole overdose is defined by the absence of a specific antidote. Official labeling confirms that no specific antidote is known for the compound. Treatment is therefore primarily symptomatic and supportive. In cases of significant overdose, procedural measures such as gastric emptying and the administration of activated charcoal should be considered. It is also noted in regulatory information that Lansoprazole is not expected to be removed from circulation by haemodialysis. Clearance of Lansoprazole is noted to be decreased in elderly patients and in those with hepatic impairment, which is a factor for consideration during supportive care.

Therapeutic Uses of Lanpo

Quick Facts

  • Relief: May help to reduce heartburn and other symptoms of acid reflux.
  • Healing: Supports the healing of sores in the lining of the stomach and small intestine.
  • Maintenance: May be used to maintain the healing of damage to the esophagus related to acid reflux.
  • Risk Reduction: Used to lower the risk of developing gastric ulcers associated with NSAID use.

What Lanpo Treats: Main Uses and Benefits

Lanpo is a medication used to support the management of certain conditions related to stomach acid. The drug is indicated for the short-term healing and symptomatic relief of active duodenal ulcers and active benign gastric ulcers.

It is also used to address Gastroesophageal Reflux Disease (GERD). In this context, Lanpo may help with the short-term treatment of heartburn and other associated symptoms. Furthermore, it supports the healing of erosive esophagitis (EE), which involves damage to the lining of the esophagus due to acid reflux. Following this initial healing phase, the drug may be prescribed to maintain the healed state of the esophagus.

Lanpo also serves as a supportive measure in certain therapeutic contexts. It may be used to reduce the risk of developing gastric ulcers in individuals who require the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Additionally, it is part of combination regimens to help eliminate H. pylori bacteria, a factor in the recurrence of duodenal ulcers.

Eligibility and Restrictions for Use

The official regulatory documents define the eligible and restricted patient populations for Lanpo (insulin glargine) based on absolute prohibitions and established clinical data.

Populations Excluded from Use

Classification Exclusion Criteria (Contraindicated)
Absolute Hypersensitivity to Lanpo or any of its excipients.
Acute During episodes of active hypoglycemia (low blood sugar).

Established and Restricted Use

Age-Related Eligibility:

  • Adults: Use is established and approved for adults with diabetes mellitus.
  • Pediatric Use: Approved for patients 2 years of age and older. Safety and effectiveness are not established in children under 2 years of age.
  • Older Adults: May require close monitoring due to the potential for age-related decline in kidney function.

Special Populations and Conditions:

  • Organ Impairment: Patients with renal impairment (kidney disease) or hepatic impairment (liver disease) require restricted use, careful monitoring, and potential dosage adjustment.
  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is conditional, requiring a careful benefit-risk assessment by a healthcare provider, as insulin needs may change.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Lanpo (Lansoprazole) based primarily on its effect of increasing gastric pH and its involvement in the hepatic Cytochrome P450 enzyme system.

Contraindicated Combination

Co-administration with Rilpivirine-containing products is formally contraindicated because the Lansoprazole-induced pH change significantly reduces Rilpivirine's systemic exposure, potentially leading to a loss of therapeutic effectiveness.

Exposure-Modifying Interactions

Interaction Type Interacting Substance(s) Official Outcome
Reduced Absorption (due to pH increase) Azole Antifungals (e.g., Ketoconazole), HIV Protease Inhibitors (e.g., Atazanavir) Substantial decrease in exposure of co-administered medicine.
Increased Absorption (due to pH increase) Digoxin Increased systemic exposure of Digoxin.
Reduced Clearance (PK/Transporter) Methotrexate Elevated and prolonged serum concentrations of Methotrexate.

Timing and Metabolic Constraints

An administration timing rule applies to Sucralfate, which must be taken at least 30 minutes after Lanpo to prevent Sucralfate from reducing and delaying Lansoprazole absorption. Lanpo is metabolized by CYP2C19 and CYP3A4 enzymes; therefore, strong inducers of these enzymes, such as the herbal product St John’s Wort, can reduce Lansoprazole plasma concentrations. Furthermore, co-administration with Warfarin has regulatory reports of increased International Normalized Ratio (INR).

Mechanism of Action

Dual Action on Ocular Fluid Outflow

This drug employs a dual mechanism that acts on two separate systems to increase the rate of fluid outflow from the eye, addressing both the conventional and uveoscleral outflow pathways simultaneously. This targeted approach modifies two distinct systems, resulting in a reduction in intraocular pressure.

Prostaglandin-Mediated Outflow Enhancement

One component of the drug is converted into an active metabolite that acts as an agonist for the Prostaglandin F2 alpha (FP) receptor. Activating this receptor initiates a cascade that leads to the remodeling of the tissue structure in the uveoscleral pathway, modifying the tissue structure to allow for increased fluid transport through this non-conventional route.

Nitric Oxide Signaling for Conventional Drainage

The second component releases nitric oxide (NO), a signaling molecule that targets the conventional outflow tissues. The NO activates soluble guanylate cyclase (sGC), causing the structural cells of the trabecular meshwork to relax and change shape. This reduction in cellular tension modulates the fluid flow resistance through the primary drainage route.

Dosage and Administration Information

Lanpo (lansoprazole) administration is defined by its specific pharmaceutical properties, requiring adherence to official instructions to ensure proper absorption and effectiveness. The medicine is primarily administered through the oral route as a delayed-release capsule or an orodispersible tablet, although an intravenous (IV) formulation is available for use when the oral route is not feasible.

The standard dosing typically involves 15 mg or 30 mg taken once daily. To optimize the drug's effect, it must be administered before eating, generally preceding the first meal of the day.

Procedurally, the oral dosage forms are designed to protect the acid-labile drug, mandating that delayed-release capsules must be swallowed whole and not crushed, chewed, or opened unless specified otherwise for administration via alternative methods.

The duration of use is structured into a short-term, acute healing course—typically 4 to 8 weeks—followed by a lower-dose maintenance phase that may extend up to 12 months or longer, based on established protocols for specific conditions. A maximum daily dose of 180 mg is indicated for Pathological Hypersecretory Conditions (ZES), requiring the dose to be divided and administered multiple times daily. Dose modification or increased monitoring is explicitly advised for patients with severe hepatic impairment due to the drug’s metabolism.

Recent Clinical Evidence

Lanpo: Recent Clinical Evidence

Overview of Studies

Research has explored the dual approach of this agent, which involves a combination of two components. Studies were designed to evaluate the potential influence on both the inflammatory and central components of pain perception in adult patients with acute non-specific lower back pain (NSLBP).

Studies have investigated the agent's role in the management of NSLBP symptoms. The primary research focus involved assessing changes in pain intensity, typically measured using scales like the Visual Analog Scale (VAS), and measuring improvements in functional outcomes, such as the Oswestry Disability Index (ODI), within the first two weeks of treatment.

Comparative and Long-term Data

Some research has compared the agent's effects against standard over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs) to evaluate whether differences in reported measures were observed, focusing on short-term efficacy and tolerability profiles.

Evidence from studies suggests that fewer studies have focused on the longer-term effects. Data collected from a small number of extension studies suggested that a change in pain scores persisted up to 8 weeks in some participants. Researchers also examined the relationship between patient adherence to the prescribed course and the reported pain scores.

Tolerability and Subgroup Research

This agent was studied in people with acute NSLBP. The frequency and type of side effects were documented during these trials. Specific studies examined the safety profile in elderly patients (participants aged 65 and older), and the frequency of adverse events was documented in this subgroup.

There are no published studies investigating the agent in people with severe kidney impairment. Research has also explored whether the combination has an impact on measures in chronic pain; however, the findings remain preliminary, and the available evidence remains limited. Overall, the collected evidence has been summarized regarding the agent's use in acute NSLBP.

Frequently Asked Questions (FAQ)

Common questions about Lanpo (FAQ)


Q: How quickly should I expect to feel the effects of Lanpo?

A: According to official product information, Lanpo works by gradually blocking acid production in the stomach. Some people may notice effects quickly, but achieving the full, sustained acid-reducing effect, based on regulatory studies, may take about one to four days.


Q: Does Lanpo build up in your system over time?

A: The active ingredient in Lanpo has a short half-life, meaning it is cleared from the bloodstream relatively quickly (around 1 to 1.5 hours). However, the therapeutic effect lasts much longer because the medicine binds irreversibly to the proton pumps in the stomach, continuing to block acid production over time.


Q: What should I do if a minor side effect from Lanpo doesn't go away?

A: If a side effect, even a minor one, is persistent or concerning, official regulatory guidance suggests that long-term or unusual side effects should be discussed with a healthcare professional. A healthcare professional can evaluate the symptom and discuss appropriate next steps.


Q: Is it better to take Lanpo in the morning or the evening?

A: Official administration instructions state that Lanpo should be taken before eating to optimize its effect. It is generally recommended to precede the first meal of the day.


Q: What kind of research has been done on the long-term effects of Lanpo?

A: Research and regulatory warnings indicate that long-term use of Lanpo, typically over one year, is associated with specific risks. These include the potential for developing Hypomagnesemia (low magnesium levels in the blood) and an increased risk of bone fracture.


Q: Is Lanpo used for any conditions other than its main approved use?

A: Yes, Lanpo has several approved uses beyond its general function of reducing acid. These include the healing of ulcers, treating conditions like Gastroesophageal Reflux Disease (GERD), and use in combination with antibiotics for the eradication of H. pylori infection.


Q: Does Lanpo affect blood pressure?

A: While the adverse event tables for Lanpo document a range of effects, changes in blood pressure, such as hypertension or hypotension, are typically listed as rare or uncommon events. Concerns about changes in blood pressure while taking this medicine should be discussed with a healthcare provider.


Q: Why is Lanpo sometimes prescribed along with another medication?

A: Lanpo is often prescribed as part of a combination therapy with specific antibiotics, such as amoxicillin and clarithromycin. This combination is used to treat and clear H. pylori bacterial infections, which can cause ulcers.


Q: Is Lanpo the same kind of medicine as other common drugs for this condition?

A: Yes, Lanpo belongs to a well-known therapeutic class of medicines called Proton Pump Inhibitors (PPIs). All medicines in this class share a common mechanism, which is to block the final step of acid secretion in the stomach lining.


Q: Are the side effects of Lanpo usually serious?

A: The most frequently reported adverse reactions in clinical studies are classified as Common, involving the Gastrointestinal System (e.g., diarrhea) and the Nervous System (e.g., headache). Serious or rare reactions are also documented but occur far less frequently.


Q: How long after stopping Lanpo will it be completely out of my system?

A: The active ingredient itself has a short half-life of approximately 1 to 1.5 hours, meaning it is quickly processed by the body. However, the time it takes for the body to return to baseline acid production after stopping the medicine is longer.


Q: Is Lanpo considered a controlled substance?

A: No, according to official regulatory classification, Lanpo (Lansoprazole) is not classified as a controlled substance.


Q: Has Lanpo been approved by the FDA (or equivalent regulatory body)?

A: Yes, the active ingredient in Lanpo, Lansoprazole, has been reviewed and approved by the FDA and other major international regulatory bodies for its stated indications.


Q: Can older adults use Lanpo without special concerns?

A: Official information indicates that older adults may be more sensitive to the medicine's effects. It is advised that these patients may require close monitoring, especially due to the potential for age-related decline in kidney function.


Q: Does Lanpo cause weight gain or loss?

A: Both weight gain and weight loss have been reported in postmarketing surveillance, meaning these events were reported by people using the drug after its initial approval. Such reports are considered rare.


Q: Can taking Lanpo affect sleep patterns?

A: Official adverse reaction reports include instances of sleep disorders and insomnia. If changes in sleep patterns are experienced after starting this medicine, it is appropriate to discuss them with a healthcare professional.


Q: Are there generic versions of Lanpo available?

A: Yes, the active ingredient in Lanpo, Lansoprazole, is widely available in generic versions for many of its formulations.


Q: Can Lanpo cause changes in mood or behavior?

A: Rare adverse reactions affecting the nervous system have been reported, including depression, agitation, anxiety, and confusion. These are not common side effects but are documented in regulatory labeling.


Q: Is there a maximum time someone can safely be on Lanpo?

A: The maximum duration of use depends on whether the drug is prescribed or purchased over-the-counter (OTC). OTC products are labeled for a 14-day course. The duration for prescription use is determined by a healthcare provider according to the condition being treated.


Q: Does Lanpo need to be stored in a special way (e.g., refrigerated)?

A: Lanpo requires specific storage conditions. It must be kept at controlled room temperature (20°C to 25°C) and protected from moisture and high heat. Prepared liquid suspensions may require refrigeration.


Q: What are the signs of a rare, serious reaction to Lanpo?

A: Rare, serious reactions can include symptoms of an allergic reaction (such as rash or swelling), signs of kidney injury (like decreased urination), or symptoms of low magnesium (such as muscle cramps or tremors). If such signs occur, it is important to seek immediate attention from a healthcare professional.


Q: How common is an allergic reaction to Lanpo?

A: While hypersensitivity is listed as an absolute contraindication, severe allergic reactions (such as SCARs) are documented as rare events. Any history of allergy to the drug should be discussed with a professional.


Q: Why is Lanpo sometimes described as a 'pro-drug'?

A: Lanpo is chemically considered a prodrug because it is an inactive compound when swallowed. It only becomes active and begins to work after it is activated by the acidic environment within the parietal cells of the stomach.


Q: Can Lanpo be taken during pregnancy or while breastfeeding?

A: Official regulatory information states that use during pregnancy is generally not recommended unless the benefit is clearly needed. Similarly, a decision must be made to either discontinue nursing or discontinue the drug while breastfeeding.


Q: Are there any long-term nutrient deficiencies associated with Lanpo use?

A: Yes, long-term use (typically over three years) is explicitly associated with the potential for Vitamin B12 deficiency. Similarly, low magnesium levels (Hypomagnesemia) are also a documented risk with extended use.


Q: Why do some people need a higher dose of Lanpo than others?

A: Dosage requirements can vary significantly based on the condition being treated. For example, much higher doses are indicated for severe conditions like Pathological Hypersecretory Conditions (Zollinger-Ellison Syndrome). Dosage may also be adjusted for patients with severe hepatic impairment (liver problems).


Q: What kind of improvements can be measured when taking Lanpo?

A: The medicine is designed to achieve measurable improvements in conditions caused by excess acid. These improvements include evidence of ulcer healing and a reduction in acid-related symptom relief, such as a decrease in heartburn frequency.

How should Lanpo be stored and disposed of?

Storage Conditions

Lanpo (Lansoprazole) must be stored according to regulatory requirements to protect the product integrity.

Condition Requirement
Temperature Store at Controlled Room Temperature: 20°C to 25°C (68°F to 77°F).
Protection Keep the container tightly closed and protect the product from moisture and high heat.
Child Safety Store all medicine out of the reach of children.

Stability of Compounded Suspension

When prepared as an oral suspension, the product must be stored under refrigeration (2°C to 8°C or 36°F to 46°F) and protected from light and freezing. The refrigerated suspension is stable for a beyond-use period of not later than 30 days.

Disposal

Unused or expired Lanpo must be disposed of according to official regulatory guidelines for safe drug disposal, which includes avoiding disposal in household drains or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanpo found in:

A-Z Index: